在2型糖尿病中基于人工智能的治疗策略的进步:一个关键的更新
Aniruddha Sen1, Palani Selvam Mohanraj2, Vijaya Laxmi2
1Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, 273008, India.
Journal of pharmaceutical analysis
|July 18, 2025
概括
本综述探讨了2型糖尿病 (T2DM) 治疗和人工智能 (AI) 的进展. 人工智能集成,特别是在胰岛素治疗中,为T2DM管理提供了个性化的护理和更好的结果.
科学领域:
- 内分泌学和新陈代谢学
- 医疗人工智能 医疗人工智能
背景情况:
- 2型糖尿病 (T2DM) 是一个重大的全球健康挑战.
- 持续需要创新的治疗策略来改善T2DM护理中的患者结果.
研究的目的:
- 审查T2DM管理中的近期治疗进展.
- 探索人工智能 (AI) 在T2DM护理中的作用和潜力,专注于个性化胰岛素治疗.
- 分析治疗进步和人工智能之间的协同作用,以提高T2DM查,诊断和治疗决策.
主要方法:
- 对当前T2DM疗法的综合文献综述,包括药物治疗,生活方式干预和新型治疗方式.
- 分析糖尿病管理中新兴的人工智能应用,如胰岛素治疗的预测建模和算法个性化等.
- 检查治疗进步和人工智能工具的整合,以改善患者的治疗结果.
主要成果:
- 最近的治疗方法在T2DM管理中显示出前景.
- 人工智能通过算法和预测建模展示了个性化胰岛素治疗的变革潜力.
- 人工智能和治疗进步之间的协同作用可以提高T2DM的查,诊断和治疗反应.
结论:
- 人工智能融入T2DM护理,特别是胰岛素治疗,提供了高度个性化和有效的管理策略.
- 人工智能和新型治疗方法之间的合作机会是打开T2DM护理未来的关键.
- 由人工智能驱动的以人为中心的方法,利用诊断标准和预测方法,比传统的T2DM管理策略有显著的进步.
相关概念视频
Diabetes: Management and Pharmacotherapy
399
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
399
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Carbohydrate Metabolism
11.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.8K
Insulin: Dosing Regimen and Adverse Effects
262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262
Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305


